Simultaneous administration of certain antihypertensive (renin–angiotensin system inhibitors and diuretics) and nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a renal toxicity syndrome known as “triple whammy” acute kidney injury (TW-AKI), yet poorly characterized at the pathophysiological level, as no specific experimental model exists on which to conduct preclinical research. Herein, we generated and characterized a rat model of TW-AKI (0.7 mg/kg/day trandolapril +400 mg/kg/day ibuprofen +20 mg/kg/day furosemide). Double treatments involving the NSAID caused a subclinical acute kidney injury, as they reduced glomerular filtration rate to a significant but not sufficient extent to increase Crpl concentration. Only the triple treatment generated an overt AKI with increased Crpl provided that animals were under partial water ingestion restriction. Histological examination revealed no evidence of tissue renal injury, and no proteinuria or makers of renal damage were detected in the urine. These findings, along with a normal fractional excretion of sodium and glucose, indicated that these drug combinations produce a prerenal type of AKI. In fact, blood pressure and renal blood flow were also reduced (most markedly following the triple combination), although renal dysfunction was more pronounced than expected for the corresponding pressure drop, supporting a key pathological role of the interference with renal autoregulation mechanisms. In summary, prerenal TW-AKI only occurs when volemia is challenged (i.e., by furosemide in partially water-deprived animals) under the effects of renin–angiotensin system inhibitors and NSAIDs. This model will facilitate further pathophysiological knowledge for a better diagnosis and clinical handling of this syndrome.
Subscribe to Journal
Get full journal access for 1 year
only $36.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441–50.
Patel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, et al. Improved blood pressure control to reduce cardiovascular disease morbidity and mortality: the standardized hypertension treatment and prevention project. J Clin Hypertens. 2016;18:1284–94.
MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, et al. Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc. 2017;6:e006986.
Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8:669–81.
Bacchi S, Palumbo P, Sponta A, Coppolino MF. Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Antiinflamm Antiallergy Agents Med Chem. 2012;11:52–64.
Abbott FV, Fraser MI. Use and abuse of over-the-counter analgesic agents. J Psychiatry Neurosci. 1998;23:13–34.
Prieto-García L, Pericacho M, Sancho-Martínez SM, Sánchez Á, Martínez-Salgado C, López-Novoa JM, et al. Mechanisms of triple whammy acute kidney injury. Pharmacol Ther. 2016;167:132–45.
Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Stricker BHC, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158:1108–12.
Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: the triple whammy revisited. Med J Aust. 2000;173:274.
Thomas MC. Diuretics, ACE inhibitors and NSAIDs—the triple whammy. Med J Aust. 2000;172:184–5.
Murugan R, Kellum JA. Acute kidney injury: what’s the prognosis? Nat Rev Nephrol. 2011;7:209–17.
Siew ED, Himmelfarb J. The inexorable rise of AKI: can we bend the growth curve? J Am Soc Nephrol. 2013;24:3–5.
Chan L, Mehta S, Chauhan K, Poojary P, Patel S, Pawar S, et al. National trends and impact of acute kidney injury requiring hemodialysis in hospitalizations with atrial fibrillation. J Am Heart Assoc. 2016;5:e004509. pii
Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, et al. World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013;8:1482–93.
Neild GH. Multi-organ renal failure in the elderly. Int Urol Nephrol. 2001;32:559–65.
Block CA, Schoolwerth AC. The epidemiology and outcome of acute renal failure and the impact on chronic kidney disease. Semin Dial. 2006;19:450–4.
Kellum JA, Hoste EAJ. Acute kidney injury: epidemiology and assessment. Scand J Clin Lab Investig. 2008;68:6–11.
Kerr M, Bedford M, Matthews B, O’donoghue D. The economic impact of acute kidney injury in England. Nephrol Dial Transplant. 2014;29:1362–8.
Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.
Fournier J-P, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL, et al. More on the “Triple Whammy”: antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury—a case/non-case study in the French pharmacovigilance database. Ren Fail. 2014;36:1166–8.
Blakeman T, Harding S, O’Donoghue D. Acute kidney injury in the community: why primary care has an important role. Br J Gen Pract. 2013;63:173–4.
Schissler MM, Zaidi S, Kumar H, Deo D, Brier ME, McLeish KR. Characteristics and outcomes in community-acquired versus hospital-acquired acute kidney injury. Nephrology. 2013;18:183–7.
Der Mesropian PJ, Kalamaras JS, Eisele G, Phelps KR, Asif A, Mathew RO. Long-term outcomes of community-acquired versus hospital-acquired acute kidney injury: a retrospective analysis. Clin Nephrol. 2014;81:174–84.
Wonnacott A, Meran S, Amphlett B, Talabani B, Phillips A. Epidemiology and outcomes in community-acquired versus hospital-acquired aki. Clin J Am Soc Nephrol. 2014;9:1007–14.
Cryer B, Barnett MA, Wagner J, Wilcox CM. Overuse and misperceptions of nonsteroidal anti-inflammatory drugs in the United States. Am J Med Sci. 2016;352:472–80.
Quiros Y, Ferreira L, Sancho-Martínez SM, González-Buitrago JM, López-Novoa JM, López-Hernández FJ. Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein. Kidney Int. 2010;78:1006–15.
Ferreira L, Quiros Y, Sancho-Martínez SM, García-Sánchez O, Raposo C, López-Novoa JM, et al. Urinary levels of regenerating islet-derived protein III β and gelsolin differentiate gentamicin from cisplatin-induced acute kidney injury in rats. Kidney Int. 2011;79:518–28.
Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79:33–45.
Quiros Y, Vicente-Vicente L, Morales AI, López-Novoa JM, López-Hernández FJ. An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. Toxicol Sci. 2011;119:245–56.
Perazella MA, Coca SG. Traditional urinary biomarkers in the assessment of hospital-acquired AKI. Clin J Am Soc Nephrol. 2012;7:167–74.
Vanmassenhove J, Glorieux G, Hoste E, Dhondt A, Vanholder R, Van Biesen W. Urinary output and fractional excretion of sodium and urea as indicators of transient versus intrinsic acute kidney injury during early sepsis. Crit Care. 2013;17:R234.
Trumper L, Monasterolo LA, Ochoa E, Elias MM. Tubular effects of acetaminophen in the isolated perfused rat kidney. Arch Toxicol. 1995;69:248–52.
Arndt C, Morgenstern B, Hawkins D, Wilson D, Liedtke R, Miser J. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol. 1999;32:93–96.
Frangeskou M, Lopez-Valcarcel B, Serra-Majem L. Dehydration in the elderly: a review focused on economic burden. J Nutr Health Aging. 2015;19:619–27.
Thomas ME, Blaine C, Dawnay A, Devonald MA, Ftouh S, Laing C, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87:62–73.
Pfaller W, Gstraunthaler G. Nephrotoxicity testing in vitro-what we know and what we need to know. Environ Health Perspect. 1998;106 Suppl 2:559–69.
Sharma A, Mucino MJ, Ronco C. Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin Pract. 2014;127:94–100. S. Karger AG
Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38:1933–53.
Emeigh Hart SG. Assessment of renal injury in vivo. J Pharmacol Toxicol Methods. 2005;52:30–45.
Solomon R, Segal A. Defining acute kidney injury: what is the most appropriate metric? Nat Clin Pract Nephrol. 2008;4:208–15.
Ronco C, Kellum JA, Haase M. Subclinical AKI is still AKI. Crit Care. 2012;16:313.
Sgouralis I, Layton AT. Theoretical assessment of renal autoregulatory mechanisms. Am J Physiol Renal Physiol. 2014;306:F1357–71.
This study was supported by grants from the Government of Spain [Instituto de Salud Carlos III (PI14/01776, DT15S/00166, PI15/01055 and PI18/00996, PI19/00588 and Retic RD016/0009/0025, REDINREN), Ministerio de Economía y Competitividad (IPT-2012-0779-010000)], FEDER funds, the Canada 150 Research Chair program and the NSERC Discovery grant program.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Prieto-García, L., Vicente-Vicente, L., Blanco-Gozalo, V. et al. Pathophysiological mechanisms underlying a rat model of triple whammy acute kidney injury. Lab Invest (2020). https://doi.org/10.1038/s41374-020-0473-9